Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
, 336 (7636), 138-42

Advice to Use Topical or Oral Ibuprofen for Chronic Knee Pain in Older People: Randomised Controlled Trial and Patient Preference Study

Affiliations
Randomized Controlled Trial

Advice to Use Topical or Oral Ibuprofen for Chronic Knee Pain in Older People: Randomised Controlled Trial and Patient Preference Study

Martin Underwood et al. BMJ.

Abstract

Objective: To determine whether older patients with chronic knee pain should be advised to use topical or oral non-steroidal anti-inflammatory drugs (NSAIDs).

Design: Randomised controlled trial and patient preference study.

Setting: 26 general practices.

Participants: People aged > or =50 with knee pain: 282 in randomised trial and 303 in preference study.

Interventions: Advice to use topical or oral ibuprofen. Primary outcome measures WOMAC (Western Ontario and McMaster Universities) osteoarthritis index, major and minor adverse effects.

Results: Changes in global WOMAC scores at 12 months were equivalent. In the randomised trial the difference (topical minus oral) was two points (95% confidence interval -2 to 6); in the preference study, it was one point (-4 to 6). There were no differences in major adverse effects in the trial or study. The only significant differences in secondary outcomes were in the randomised trial. The oral group had more respiratory adverse effects (17% v 7%,95% confidence interval for difference -17% to -2%), the change in serum creatinine was 3.7 mmol/l less favourable (0.9 micromol/l to 6.5 micromol/l); and more participants changed treatments because of adverse effects (16% v 1%, -16% to -5%). In the topical group more participants had chronic pain grade III or IV at three months, and more participants changed treatment because of ineffectiveness.

Conclusions: Advice to use oral or topical preparations has an equivalent effect on knee pain over one year, and there are more minor side effects with oral NSAIDs. Topical NSAIDs may be a useful alternative to oral NSAIDs.

Trial registration: ISRCTN 79353052.

Conflict of interest statement

Competing interests: MU has received speaker fees from Pfizer, the manufacturers of celecoxib.

Figures

None
Fig 1 Flow chart of recruitment to both studies
None
Fig 2 Participant follow-up in randomised trial
None
Fig 3 Participant follow-up in preference study

Comment in

Similar articles

See all similar articles

Cited by 21 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

Substances

Associated data

Feedback